clofibric acid has been researched along with Muscle Disorders in 9 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
| Excerpt | Relevance | Reference |
|---|---|---|
| "(1) Renal failure, either pre-existing or induced by a nephrotoxic drug, increases the risk of adverse effects in patients taking colchicine; (2) Combining colchicines with a macrolide (except for spiramycin) carries a risk of life-threatening pancytopenia; (3) Ciclosporin co-administration can aggravate the neuromuscular adverse effects of colchicine; (4) Combining colchicine with lipid-lowering drugs (statins and fibrates) can cause myopathy; (5) Several mechanisms have been implicated: competition for cytochrome P450 or P-glycoprotein, additive adverse effects (especially on muscle), and colchicine accumulation due to a reduction in its renal excretion; (6) Patients with gout should use colchicine only after failure of symptomatic treatment: ice application, paracetamol, and possibly ibuprofen, a nonsteroidal antiinflammatory drug with well-documented adverse effects; (7) If colchicine is nevertheless used, it should be at the minimum effective dose." | 3.74 | Colchicine: serious interactions. ( , 2008) |
| "Rhabdomyolysis is a rare side effect of statin therapy with an estimated incidence of 0." | 2.43 | [Myopathies under therapy with lipid-lowering agents]. ( Hartung, HP; Köller, H; Neuhaus, O; Schroeter, M, 2005) |
| " This may at least partially explain the lower incidence of myopathy with fenofibrate compared with gemfibrozil when combined with statins." | 2.43 | Fibrates in combination with statins in the management of dyslipidemia. ( Jacobson, TA; Zimmerman, FH, 2006) |
| "A systematic review of cohort studies, randomized trials, voluntary notifications to national regulatory authorities, and published case reports was undertaken to assess the incidence and characteristics of adverse effects in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins." | 2.43 | Statin safety: a systematic review. ( Law, M; Rudnicka, AR, 2006) |
| " Due to the adverse effects provoked by hypolipidemic drugs on skeletal muscle function, we also investigated the blocking activity of S-2 and S-4 on skeletal muscle membrane chloride channel conductance and found that these ligands have a pharmacological profile more beneficial compared to fibrates currently used in therapy." | 1.35 | New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function. ( Conte Camerino, D; Fracchiolla, G; Laghezza, A; Lavecchia, A; Loiodice, F; Mazza, F; Montanari, R; Novellino, E; Piemontese, L; Pierno, S; Pochetti, G; Tortorella, P, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (77.78) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fracchiolla, G | 1 |
| Laghezza, A | 1 |
| Piemontese, L | 1 |
| Tortorella, P | 1 |
| Mazza, F | 1 |
| Montanari, R | 1 |
| Pochetti, G | 1 |
| Lavecchia, A | 1 |
| Novellino, E | 1 |
| Pierno, S | 1 |
| Conte Camerino, D | 1 |
| Loiodice, F | 1 |
| Carvalho, AA | 1 |
| Lima, UW | 1 |
| Valiente, RA | 1 |
| Köller, H | 1 |
| Neuhaus, O | 1 |
| Schroeter, M | 1 |
| Hartung, HP | 1 |
| Jacobson, TA | 1 |
| Zimmerman, FH | 1 |
| Law, M | 1 |
| Rudnicka, AR | 1 |
| Florentin, M | 1 |
| Liberopoulos, EN | 1 |
| Mikhailidis, DP | 1 |
| Elisaf, MS | 1 |
| Heidemann, H | 1 |
| Bock, KD | 1 |
| Bardosi, A | 1 |
| Scheidt, P | 1 |
| Goebel, HH | 1 |
4 reviews available for clofibric acid and Muscle Disorders
| Article | Year |
|---|---|
[Myopathies under therapy with lipid-lowering agents].
Topics: Anticholesteremic Agents; Clofibric Acid; Diagnosis, Differential; Dose-Response Relationship, Drug; | 2005 |
Fibrates in combination with statins in the management of dyslipidemia.
Topics: Clofibric Acid; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductas | 2006 |
Statin safety: a systematic review.
Topics: Adverse Drug Reaction Reporting Systems; Chemical and Drug Induced Liver Injury; Clofibric Acid; Cre | 2006 |
Fibrate-associated adverse effects beyond muscle and liver toxicity.
Topics: Animals; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Clofibric Acid; Humans; L | 2008 |
5 other studies available for clofibric acid and Muscle Disorders
| Article | Year |
|---|---|
New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function.
Topics: Animals; Cell Line, Tumor; Chloride Channels; Chlorides; Clofibric Acid; Crystallography, X-Ray; Dru | 2009 |
Colchicine: serious interactions.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase Inhibitors; Clofibric Acid; Colchicine; Cycl | 2008 |
Statin and fibrate associated myopathy: study of eight patients.
Topics: Adult; Aged; Anticholesteremic Agents; Biopsy; Clofibric Acid; Creatine Kinase; Drug Therapy, Combin | 2004 |
[Rhabdomyolysis with acute renal failure due to bezafibrate].
Topics: Acute Kidney Injury; Bezafibrate; Clofibrate; Clofibric Acid; Humans; Male; Middle Aged; Muscular Di | 1981 |
Mitochondrial myopathy--a result of clofibrate/etofibrate treatment? Case report.
Topics: Aged; Clofibrate; Clofibric Acid; Humans; Hypolipidemic Agents; Kearns-Sayre Syndrome; Male; Microsc | 1985 |